SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

AST SpaceMobile, Inc. engages in building a broadband cellular network in space to operate directly with standard, unmodified mobile devices based on an intellectual property and patent portfolio. It focuses on providing mobile broadband services with global coverage to all end-users, without the need to purchase special equipment. The company was founded by Abel Avellan on May 31, 2017 and is headquartered in Midland, TX.

AST SpaceMobile Inc - Ordinary Shares - Class A

AST SpaceMobile Inc

AST SpaceMobile is facing heavy sell-side pressure following the announcement of a $1 billion convertible senior note offering, with community debate sharply divided between those viewing the dilution as a strategic move to accelerate infrastructure deployment and critics expressing frustration over management's previous statements regarding funding. Many investors are currently monitoring key support levels as the market balances short-term volatility against the company's long-term goal of scaling its satellite constellation.

Taiwan Semiconductor Manufacturing Co., Ltd. engages in the manufacture and sale of integrated circuits and wafer semiconductor devices. Its chips are used in personal computers and peripheral products, information applications, wired and wireless communications systems products, and automotive and industrial equipment including consumer electronics such as smartphones, digital television, game consoles, and digital cameras. The company was founded by Chung Mou Chang on February 21, 1987 and is headquartered in Hsinchu, Taiwan.

Taiwan Semiconductor Manufacturing - ADR

TSM is currently trending as investors brace for pivotal Q2 earnings, with the market intensely focused on whether the foundry giant's guidance can justify high valuations and confirm sustained AI infrastructure demand. The community is actively debating the stock's role as the primary engine of the AI boom, with traders utilizing short-dated options to hedge against potential post-earnings volatility while long-term investors weigh the impact of rising capex and semiconductor supply chain constraints.

Atai Beckley, Inc. is a clinical-stage biopharmaceutical company focused on developing effective, rapid-acting, and convenient mental health treatments. The company is headquartered in New York, NY.

AtaiBeckley Inc.

AtaiBeckley shares are surging following a Bloomberg report that Eli Lilly is in advanced talks to acquire the psychedelic drug developer, with community sentiment focused on the potential for a high-premium buyout and a possible sector-wide bidding war. Investors are actively debating the fair valuation of the company's BPL-003 asset and whether to capitalize on recent gains or hold for further upside in the rapidly evolving psychedelic medicine landscape.

Apple, Inc. engages in the design, manufacture, and sale of smartphones, personal computers, tablets, wearables and accessories, and other varieties of related services. It operates through the following geographical segments: Americas, Europe, Greater China, Japan, and Rest of Asia Pacific. The Americas segment includes North and South America. The Europe segment consists of European countries, as well as India, the Middle East, and Africa. The Greater China segment comprises China, Hong Kong, and Taiwan. The Rest of Asia Pacific segment includes Australia and Asian countries. Its products and services include iPhone, Mac, iPad, AirPods, Apple TV, Apple Watch, Beats products, AppleCare, iCloud, digital content stores, streaming, and licensing services. The company was founded by Steven Paul Jobs, Ronald Gerald Wayne, and Stephen G. Wozniak in April 1976 and is headquartered in Cupertino, CA.

Apple Inc

Apple is trending as investors digest news of potential AI chip acquisitions and partnerships aimed at strengthening its internal infrastructure. The stock is seeing heavy community debate, with bulls highlighting the long-term potential of the Apple ecosystem and recent Chinese regulatory approvals for AI deployment, while some bears express caution over its current valuation and slowing hardware upgrade cycles.

Compass Pathways Plc is a biotechnology company, which provides mental health care services. It focuses on improving the lives of those who are suffering with mental health challenges and who are not helped by current treatments. The company was founded by Goldsmith George Jay and Malievskaia Ekaterina in 2016 and is headquartered in London, the United Kingdom.

Compass Pathways Plc - ADR

COMPASS Pathways

COMPASS Pathways is trending as the market anticipates key Phase 3 durability data for its COMP360 psilocybin therapy, a critical milestone for its rolling NDA submission and potential commercialization. Investors are actively discussing the sector's regulatory momentum following new FDA guidance for psychedelic research, while debating the significance of recent consolidation in the stock price as a potential setup for further gains.

UnitedHealth Group, Inc. engages in the provision of health care coverage, software, and data consultancy services. It operates through the following segments: UnitedHealthcare, OptumHealth, OptumInsight, and OptumRx. The UnitedHealthcare segment utilizes Optum's capabilities to help coordinate patient care, improve affordability of medical care, analyze cost trends, manage pharmacy benefits, work with care providers more effectively, and create a simpler consumer experience. The OptumHealth segment provides health and wellness care, serving the broad health care marketplace including payers, care providers, employers, government, life sciences companies, and consumers. The OptumInsight segment focuses on data and analytics, technology, and information to help major participants in the healthcare industry. The OptumRx segment offers pharmacy care services. The company was founded by Richard T. Burke in January 1977 and is headquartered in Eden Prairie, MN.

Unitedhealth Group Inc

UnitedHealth Group is seeing increased investor attention as the company approaches its upcoming earnings report, with community members closely tracking institutional accumulation and technical indicators suggesting potential breakout momentum. The stock is currently viewed by many as a defensive safe haven amidst broader market volatility, with focus shifting toward whether strong operational performance and AI-driven efficiencies can drive a sustained move higher.

PayPal Holdings, Inc. engages in the development of technology platforms that enable digital payments and simplifies commerce experiences on behalf of merchants and consumers worldwide. Its solutions include PayPal, PayPal Credit, Braintree, Venmo, Xoom, and Paydiant products. The firm also enables consumers to exchange funds with merchants using funding sources, which include bank account, PayPal account balance, PayPal Credit account, credit, and debit card or other stored value products. It operates through United States and Other Countries geographical segments. The company was founded in December 1998 and is headquartered in San Jose, CA.

PayPal Holdings Inc

PayPal is surging as investors react to a reported joint $53 billion buyout bid from Stripe and Advent International at $60.50 per share. The community is actively debating whether this represents a "lowball" offer, with many bullish investors and analysts arguing that the company's strong free cash flow and strategic value justify a counter-offer closer to $80-$100 per share.

SK hynix, Inc. engages in the manufacture and sale of semiconductor products. Its products include dynamic random access memory, flash memory, complementary metal oxide semiconductor image sensor, and others. The company was founded on October 15, 1949 and is headquartered in Icheon, South Korea.

SK Hynix Inc - ADR

SK Hynix is currently a focal point of intense market volatility following its recent U.S. listing, which has triggered aggressive speculation and significant volume in both the ADR and newly launched leveraged ETFs. Community sentiment is deeply divided as traders debate whether the stock represents a structural AI memory play with room for further appreciation or an overextended momentum trade facing valuation normalization and pressure from the underlying Korean market.

McDonald's Corp. engages in the operation and franchising of restaurants. The firm operates through the following segments: U.S., International Operated Markets, and International Developmental Licensed Markets and Corporate. The U.S. segment focuses its operations on the United States. The International Operated Markets segment consists of operations and the franchising of restaurants in Australia, Canada, France, Germany, Italy, the Netherlands, Russia, Spain, and the U.K. The International Developmental Licensed Markets and Corporate segment consists of developmental licensee and affiliate markets in the McDonald’s system. Its products include Big Mac, Quarter Pounder with Cheese, Filet-O-Fish, several chicken sandwiches, Chicken McNuggets, wraps, McDonald's Fries, salads, oatmeal, shakes, McFlurry desserts, sundaes, soft serve cones, pies, soft drinks, coffee, and McCafe beverages. The company was founded by Raymond Albert Kroc on April 15, 1955 and is headquartered in Chicago, IL.

McDonald`s Corp

McDonald's Corp

McDonald's is currently a major focus for traders as the stock tests long-term support levels near 52-week lows, with the community actively debating whether it presents a contrarian value opportunity or a long-term decline. Investors are polarized between those loading up on shares as a defensive hedge and bears pointing to waning foot traffic, menu pricing struggles, and the impact of the fast-food landscape as reasons for further downside.

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products include diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly on May 10, 1876 and is headquartered in Indianapolis, IN.

Lilly(Eli) & Co

Eli Lilly is trending as investors digest news of its active takeover talks with psychedelic drug developer AtaiBeckley, a move seen as a strategic expansion into the next-generation mental health market. Community sentiment is largely focused on the potential premium for Atai shareholders and how this acquisition fits into Lilly's broader strategy of aggressive M&A to secure a dominant position in emerging medical segments.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Merus Stock Soars To All-Time High As Genmab Announces $8B Takeover — Analysts Turn Cautious, Retail Crowd Cheers The Deal

Equity

The $8 billion all-cash deal gives Genmab full ownership of Merus’ late-stage antibody therapy petosemtamab, which has received two FDA Breakthrough Therapy Designations for head and neck cancer.

Merus Buyout Rumor Gets Retail Traders Buzzing — Genmab Said To Be Leading The Race

Merus’ cancer drug petosemtamab, developed for head and neck tumors, has shown stronger results than the current standard of care and is projected to top $1 billion in annual sales by 2030.

Genmab A/S is an international biotechnology company, which engages in the development of human antibody therapeutics for the treatment of cancer and other diseases. Its product pipeline includes daratumumab, marketed as DARZALEX for the treatment of certain indications of multiple myeloma, teprotumumab-trbw marketed as TEPEZZA for the treatment of thyroid eye disease, and ofatumumab, marketed as Arzerra for the treatment of certain indications of chronic lymphocytic leukemia. The company was founded by Donald Lee Drakeman, Florian Schonharting, and Jan G. J. van de Winkel on June 11, 1998, and is headquartered in Copenhagen, Denmark.

Genmab - ADR

Neutral Sentiment

$100+

$80 - $99.99

$70 - $79.99

$60 - $69.99

Stripe and private equity firm Advent International just submitted a joint takeover offer for PayPal ($PYPL) at $60.50 per share, valuing the company at more than $53 billion - a roughly 28% premium to Tuesday's close. What do you think PayPal is really worth? Cast your vote and explain your reasoning in the comments.

What should PayPal ($PYPL) be worth in a takeover deal?

Current Price	$29.08
Prev Close	$28.73
Open	$29.02
Dividend Yield	0.00%
50-Day Moving Average	$26.57
Beta	0.65
Avg. Volume	1.68M
PE Ratio	21.72

52-Week High	$35.43
52-Week Low	$21.00
Market Capitalization	$17.3B
EPS (Annual)	$1.55
Price to Book	3.14
Revenue Per Employee	$1.23M

Feed

News

Sentiment

Fundamentals

Info

GMXAYGENMAB A/S/S ADR

Latest GMXAY News